Combination mTORC1/2 and BCL- X<sub>L</sub> inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer.
Sarah Sammons(Dana-Farber Cancer Institute), Kris C. Wood(Duke University), P. Kelly Marcom(Duke University), Suzanne E. Wardell(Duke University), Donald P. McDonnell(Duke University), Grace R. Anderson(Duke University)
Cited by 2
Related Papers
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717
Genetic/Familial High-Risk Assessment: Breast and Ovarian
|Journal of the National Comprehensive Cancer Network|2010|650
Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer
|Nature Communications|2021|336
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015
|Journal of the National Comprehensive Cancer Network|2016|293